Delving into the Latest Updates on Cladribine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(2R,3S,5R)-5-(6-amino-2-chloropurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol, 2-Chloro-2'-deoxy-beta-adenosine, 2-Chloro-2'-deoxyadenosine

+ [32]

Target

RNRs

Action

inhibitors

Mechanism

RNR inhibitors(Ribonucleotide reductase inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesNervous System Diseases+ [4]

Active Indication

Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingMultiple sclerosis relapse+ [9]

Inactive Indication

Neuromyelitis Optica

Originator Organization

Lipomed AG

Active Organization

Zhejiang Hisun Pharmaceutical Co., Ltd.

EMD Serono, Inc.Merck Europe BV

+ [7]

Inactive Organization

EMD Serono Research & Development Institute, Inc.

Chord Therapeutics SA

Janssen Pharmaceuticals, Inc.

+ [1]

License Organization

Merck KGaA

Chord Therapeutics SA

BioNxt Solutions, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (26 Feb 1993),

Hairy Cell Leukemia

RegulationOrphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (South Korea)

Login to view timeline

Structure/Sequence

Molecular FormulaC10H12ClN5O3

InChIKeyPTOAARAWEBMLNO-KVQBGUIXSA-N

CAS Registry4291-63-8

The objective of the study is to evaluate the effectiveness of CladT, in terms of disease stability and safety, as the last treatment option in ageing MS patients vs treatment continuation and discontinuation This observational study will use database from local cohorts (from France, Belgium, Switzerland). Patients included must meet the inclusion criteria: RRMS diagnosis for more than 10 years without secondary progression, no evidence of disease activity (no relapse, no new MRI lesion, no EDSS progression) for more than 5 years under a DMT, age≥ 45-year-old.
Analyses will be using dynamic propensity score to match patients who stopped treatment with patients who had the same probability of continuing / stopping current treatments but took CladT as exit therapy. Patients with a minimum of 24 months follow up will be included.
We will ensure that CladT provide disease stability compared to treatment continuation / discontinuation in ageing MS patients by measuring:
* the percentage of patients free of relapse, and time to first relapse, defined as the appearance, recurrence, or aggravation of neurological symptoms for a period of at least 24 hours without fever.
* the percentage of patients free of EDSS progression confirmed for at least 6 months and until the end of patient follow up.
* the percentage of patients free of MRI activity, defined as new or enlarged T2 lesions compared with the previous brain MRI scan or gadolinium enhancing T1 lesions.

Start Date01 Jun 2025

Sponsor / Collaborator

Les Hopitaux Universitaires de Strasbourg

NCT05766514

/ WithdrawnPhase 2IIT

Phase II Prospective Randomized Control Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

This phase II, open-label, randomized trial will compare the efficacy of the novel regimen of cladribine/low-dose cytarabine alternating with decitabine to the current standard of care regimen of hypomethylating agents (decitabine or azacitidine) plus venetoclax in patients with acute myeloid leukemia (AML) or high-grade myelodysplastic syndrome (MDS) who are either elderly or unfit for intensive induction. Subjects will be randomized to be treated with either cladribine/low-dose cytarabine alternating with decitabine (Arm A) or decitabine or azacitadine plus venetoclax (Arm B).

Start Date01 Apr 2025

Sponsor / Collaborator

University of Florida

100 Clinical Results associated with Cladribine

Login to view more data

100 Translational Medicine associated with Cladribine

Login to view more data

100 Patents (Medical) associated with Cladribine

Login to view more data

3,562

Literatures (Medical) associated with Cladribine

01 Jun 2025·Multiple Sclerosis and Related Disorders

Serological screening and Vaccine Update in a cohort of Multiple Sclerosis Patients as a strategy to prevent infection reactivation during immunosuppressant therapy

Article

Author: Berezin, Eitan Naaman ; Reis, Gelvana Flávio Barreto ; de Castro, Andrea de Carvalho Anacleto Ferrari

INTRODUCTION:

Serological screening and vaccination play a crucial role in preventing infectious complications in patients with Multiple Sclerosis (MS). Standardization of tests and vaccination protocols are essential in patients undergoing treatment.

OBJECTIVE:

This study aimed to assess susceptibility to infectious diseases through serological tests and vaccine update of MS patients.

METHODS:

A cross-sectional study was conducted on patients treated by the neurology service of the Metropolitan University of Santos between February 2021 and June 2023. Serological screening and vaccine recommendations were performed by an infectious disease specialist.

RESULTS:

A total of 119 patients were included, with a mean age of 45.7 years. The sample was 68.1 % female and 31.9 % male, and vaccination update was performed for 64 (53.8 %) patients. MS treatments included: Glatiramer Acetate, Natalizumab, Fingolimod, Dimethyl Fumarate, Ocrelizumab and cladribine (Cladribine) and corticoid for MS flare-ups. Seroprevalence was: 66.0 % for the JC virus, 61.4 % Toxoplasmosis, 50.9 % Mononucleosis, 84.5 % Cytomegalovirus, 85.4 % Measles, 72.2 % Mumps, 92.6 % Rubella, and 94.2 % Varicella. No cases of HIV, HCV, HBV, HTLV or syphilis were detected. Vaccine cover was: 75 % influenza, 68.7 % Hepatitis B, 64.2 % Hepatitis A, 34.4 % HPV, 85 % COVID-19, 1.56 % Herpes Zoster, Diphtheria, Tetanus and Pertussis, 70 % DT, 6.5 % DTaP, 53 % anti-pneumococcal with Pn-23 and 31 % with Pn-13, 48.4 % Haemophilus influenzae b, 39 % Meningococcal C and 20.3 % ACWY.

CONCLUSION:

MS patients using immunosuppressant therapy may be susceptible to vaccine-preventable infectious diseases. The study demonstrates the feasibility of vaccine updates, and infectious diseases specialists can contribute assessing infection risks and providing individualized vaccines recommmendations.

01 May 2025·Multiple Sclerosis and Related Disorders

First insights into the safety and effectiveness of additional courses with cladribine tablets under real-world conditions

Article

Author: Schlemilch-Paschen, Sylke ; Kleinschnitz, Christoph ; Woitschach, Lara ; Kühnler, Benedicta ; Kowarik, Markus C ; Schwab, Matthias ; Skuljec, Jelena ; Cepek, Lukas ; Rau, Daniela ; Ernst, Michael ; Pul, Refik

BACKGROUND:

Oral cladribine for relapsing multiple sclerosis (RMS) is administered in a cumulative dose of 3.5 mg/kg body weight over the first 2 years, followed by a 2-year drug-free interval. There is a lack of evidence on resuming cladribine therapy in year 5.

OBJECTIVE:

To evaluate safety and effectiveness of additional cladribine courses in patients with RMS.

METHODS:

Adult patients with highly active RMS who completed 5 years following cladribine initiation were included in this retrospective analysis if they received one or two additional cladribine courses or remained treatment-free through year 5 (control group). Outcome parameters included lymphocyte counts, adverse events, relapse rate and EDSS.

RESULTS:

Out of 166 available patients, 48 and 13 patients received one and two additional cladribine courses, respectively, and 105 patients remained treatment-free. Administering a third and fourth course of cladribine did not trigger any serious adverse events attributable to the therapy. Elevated serum transaminase levels following additional cladribine courses did not exceed 2.5-fold the ULN. The lymphocyte profile following the third and fourth course was consistent with observations reported after the first and second course. Relapse activity remained low following redosing and in the control group. EDSS remained stable in redosed patients.

CONCLUSIONS:

Administering additional cladribine courses is an effective option to maintain disease control and did not trigger any serious adverse events attributable to the therapy. Patients with elevated serum transaminase levels should be regularly monitored.

15 Apr 2025·CANCER

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single‐center, single‐arm, phase 2 trial

Article

Author: Goulart, Hannah ; Alvarado, Yesid ; Haddad, Fadi G. ; Atluri, Himachandana ; Pemmaraju, Naveen ; Jain, Nitin ; Rausch, Caitlin ; Kadia, Tapan M. ; Yilmaz, Musa ; Garcia‐Manero, Guillermo ; Borthakur, Gautam ; DiNardo, Courtney D. ; Loghavi, Sanam ; Jabbour, Elias ; Ravandi‐Kashani, Farhad ; Kantarjian, Hagop ; Daver, Naval ; Marx, Kayleigh R.

Abstract:

Background:

The treatment of relapsed and/or refractory (R/R) acute myeloid leukemia (AML) remains challenging because of poor responses to chemotherapy. Efforts to improve outcomes have included the use of high‐dose cytarabine in combination with nucleoside analogs, such as cladribine. The authors evaluated combined cladribine, idarubicin, and cytarabine (CLIA) in a phase 2 trial of 66 patients with R/R AML.

Methods:

Patients received induction with cladribine 5 mg/m2 intravenously (days 1–5), cytarabine 1000 mg/m2 intravenously (days 1–5), and idarubicin 10 mg/m2 intravenously (days 1–3; CLIA). Sorafenib 400 mg twice daily (days 1–14) was added for FLT3‐mutated AML.

Results:

The composite response rate (complete remission [CR] plus complete remission with incomplete hematologic recovery [CRi]) was 33%; salvage 1 (S1) patients (n = 35) had a CR/CRi rate of 49%. After a 61‐month median follow‐up, the median overall survival (OS) was 7.9 months, with a median relapse‐free survival (RFS) of 9.1 months for those in CR/CRi. The median OS for S1 patients was 12 months, with a median RFS of 10.3 months. For those who received CLIA with sorafenib (n = 22), the CR/CRi rate was 41%, median OS was 8.8 months, and median RFS was 3.8 months. Landmark analysis demonstrated superior OS for patients who proceeded to transplantation compared with patients who did not (median OS, 78 vs. 8.8 months, respectively; p < .001). The 4‐week and 8‐week mortality rates were 6% and 17%, respectively. Most grade >3 adverse events were related to infection and elevated liver function tests.

Conclusions:

CLIA is effective for patients with R/R AML and offers a safety profile similar to that of other intensive regimens (ClinicalTrials.gov identifier NCT02115295).

95

News (Medical) associated with Cladribine

22 Apr 2025

·www.globenewswire.com

Trethera To Participate in Panel Discussion and Research Poster Competition At Los Angeles Bioscience Ecosystem Summit 2025

LOS ANGELES, April 22, 2025 (GLOBE NEWSWIRE) -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announces a forthcoming panel discussion and poster presentation at the 7th Annual Los Angeles Bioscience Ecosystem Summit 2025 (“LABEST”). Panel Discussion Details: Title: BioSuccess in Los AngelesCEO Panelists: Ken Schultz (Trethera), Daniel Gil (Pelage), Dina Leeds (CleopatraRx), and Bethany Mancilla (Capsida)Moderator: Amir Naiberg, Associate Vice Chancellor, UCLA; CEO and President, UCLA Technology Development GroupLocation: Centennial Ballroom, 1st floor, Luskin Conference CenterDate: Thursday, May 22, 2025 at 2PM Poster Details: Title: First-in-Class Clinical Stage Deoxycytidine Kinase Inhibitor Blocks Inflammatory Bowel Disease Symptoms in an Adoptive CD4 T Cell Transfer Mouse ModelAuthors: Peter M. Clark, PhD; Kenneth A. Schultz, MD; KM Ryan, BSCategory: Immunity, Inflammation, Infection and Transplantation (I3T)Location: Pearl Cohen Scientific Poster Competition, Luskin Conference CenterDate: Thursday, May 22, 2025 at 4PM LABEST 2025 is the premier showcase for bioscience innovation in Los Angeles County and is produced by the UCLA Technology Development Group. The conference attracts over 1,500 life science industry professionals from the world’s leading pharmaceutical companies, venture capital firms, and research institutions. LABEST is intended to promote awareness of the growing life science entrepreneurial ecosystem in Los Angeles and to foster partnerships with the biotechnology and life science industry. Poster co-author Peter M. Clark is an Associate Professor of Molecular and Medical Pharmacology at the David Geffen School of Medicine and Crump Institute for Molecular Imaging at UCLA. Dr. Clark identified the metabolic enzyme deoxycytidine kinase, dCK, as a key and targetable enzyme required for aberrant T and B cell activation in models of autoimmune diseases, such as Crohn’s disease and lupus. The Clark lab aims to develop novel, first-in-class, drug therapies for cancer and autoimmune diseases. Figure 1: Biochemical pathways for the supply of deoxyribonucleoside triphosphate pools. The salvage pathway becomes upregulated during autoimmune diseases. FDA approved drugs blocking the de novo pathway include Aubagio (teriflunomide), Mavenclad (cladribine), and CellCept (mycophenolate mofetil). About TretheraTrethera is a clinical stage, privately held, biopharmaceutical company dedicated to pioneering the development of novel treatments for autoimmune diseases and cancers. Founded by prominent UCLA scientists, Trethera is led by experienced management and board members. Trethera's innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally administered capsule twice designated by the FDA as an Orphan Drug. TRE-515 is a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth, and certain autoimmune diseases might also respond to TRE-515 treatment. Trethera is developing TRE-515 for use as a monotherapy or in combination to precisely target a metabolic vulnerability of cancer or autoimmune diseases that will transform outcomes for patients. For more information, please visit us at trethera.com or e-mail Investor Relations at ir@trethera.com. You can also follow Trethera on Facebook and LinkedIn. Note on Forward-Looking StatementsAll statements other than statements of historical facts included in this press release that address activities, events or developments that Trethera believes or anticipates will or may occur in the future are “forward-looking statements,” which may often, but not always, be identified by the use of such words as "may," "might," "will," "will likely result," "would," "should," "estimate," "plan," "project," "forecast," "intend," "expect," "anticipate," "believe," "seek," "continue," "target" or the negative of such terms or other similar expressions. Although Trethera has a reasonable basis for the forward-looking statements contained herein, Trethera cautions that such statements are based on current expectations about future events and are subject to risks, uncertainties and factors relating to medical and scientific research, all of which are difficult to predict and many of which are beyond Trethera’s control, that may cause actual results to differ materially from those expressed or implied by the forward-looking statements in this press release. These potential risks and uncertainties include, without limitation: the extent to which development of any novel cancer therapies or therapies for autoimmune diseases succeeds; whether Trethera would obtain the necessary regulatory approvals to commence human trials or commercialize TRE-515 or any novel therapies resulting from such research; Trethera successfully implementing its growth strategy, including that relating to its disease therapies; the effects of the global Covid-19 pandemic; changes in economic conditions; competition; and risks and uncertainties applicable to the business of Trethera. The statements in this press release speak only as of the date hereof and Trethera does not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise. The Company intends that all forward-looking statements be subject to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a3669834-fb66-4439-930d-931d3a67f1b7

Orphan DrugOligonucleotide

12 Mar 2025

·pmlive.com

Merck KGaA’s Mavenclad tablets recommended by NICE for wider MS use

Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The health technology assessment agency has recommended in final draft guidance that the short-course oral therapy be used on the NHS as a first-line treatment option for adults with active relapsing‐remitting MS (RRMS) when high-efficacy disease-modifying therapies (DMTs) would be considered. The drug, which was previously only recommended by NICE as an option for highly active RRMS, a more severe form of the neurological disorder, offers patients greater flexibility by reducing the frequency of hospital visits and daily treatment requirements. Affecting more than 150,000 people in the UK, MS occurs when the immune system attacks the protective myelin sheath that covers the nerves and disrupts communication between the brain and the rest of the body. Symptoms vary, but can include extreme fatigue, blurred vision, numbness or tingling in the limbs and problems with strength and coordination. RRMS, characterised by attacks of worsening neurologic function followed by partial or complete recovery periods, accounts for about 85% of initial diagnoses, while primary progressive, which refers to patients who have stopped experiencing relapses but continue to accumulate disability, is much less common. Mavenclad, which targets lymphocytes thought to be integral to the pathological process of relapsing MS, can be taken at home and consists of a maximum of ten days of treatment in the first year and ten days in the second year. NICE’s latest decision on the drug was supported by clinical and real-world evidence demonstrating that Mavenclad can reduce MS relapse rates and slow disability progression. The agency is now expected to issue final guidance for England in April, with anticipated access in Wales and Northern Ireland to follow. Stuart Hill, medical director at Merck UK and Ireland, said: “We are pleased that NICE has recognised the benefit of [Mavenclad] tablets and that more people living with the impact of RRMS are able to access this first-line treatment. “We look forward to the final NICE guidance and remain committed to supporting people living with MS to live fuller, more independent lives.”

Drug Approval

06 Mar 2025

·www.fiercebiotech.com

Merck KGaA fails midphase lupus trial, says totality of data support further development

The importance of enpatoran to Merck has increased as other prospects have flamed out. \n One of Merck KGaA’s leading immunology assets has flunked a phase 2 lupus trial. Despite the primary endpoint miss, Merck has concluded further development is warranted in light of responses seen in subgroups and a recent win in another form of the disease.Merck tested its oral TLR7/8 inhibitor enpatoran in two forms of lupus. The company reported positive phase 2 data from the cohort of cutaneous lupus erythematosus (CLE) patients late last year. Thursday, Merck revealed the systemic lupus erythematosus (SLE) cohort was less successful. The SLE arm missed its primary endpoint, which assessed responses on a composite scale after 24 weeks of daily dosing.The German drugmaker said it saw “promising responses” in predefined subgroups of patients. Considering the subgroup responses, CLE results and safety profile, Merck judged that the totality of data supports further development.Merck is yet to share the data underpinning its conclusion, with updates to date limited to qualitative assessments of the results. Peter Guenter, CEO of healthcare at Merck, disclosed the CLE success at the company’s Capital Markets Day in October, telling analysts the trial found “very strong and unambiguous proof of concept in cutaneous lupus.” Enpatoran, which Merck is also studying in idiopathic inflammatory myopathies, is one of the two most advanced assets in the company’s neurology and immunology pipeline. Cladribine, the other advanced candidate, is in phase 3 development as a treatment for generalized myasthenia gravis.The importance of enpatoran and cladribine to Merck has increased as other prospects have flamed out. Four years ago, Merck named enpatoran, evobrutinib and xevinapant as three important clinical programs that it expected to help fuel its “next wave of growth.” Evobrutinib failed a phase 3 trial in late 2023 and was quickly axed, while Merck dropped xevinapant in June 2024 after an interim phase 3 analysis.

Phase 3Phase 2Clinical Result

100 Deals associated with Cladribine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01370	Cladribine	L04AA40 L01BB04	DB00242

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Multiple Sclerosis	United States	EMD Serono, Inc.	29 Mar 2019
Multiple Sclerosis, Relapsing-Remitting	Canada	EMD Serono, Inc.	30 Nov 2017
Multiple sclerosis relapse	European Union	Merck Europe BV	22 Aug 2017
Multiple sclerosis relapse	Iceland	Merck Europe BV	22 Aug 2017
Multiple sclerosis relapse	Liechtenstein	Merck Europe BV	22 Aug 2017
Multiple sclerosis relapse	Norway	Merck Europe BV	22 Aug 2017
Anemia	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	15 Nov 2005
Neutropenia	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	15 Nov 2005
Thrombocytopenia	China	Zhejiang Hisun Pharmaceutical Co., Ltd.	15 Nov 2005
Mantle-Cell Lymphoma	Japan	Clinigen KK	16 Dec 2002
Non-Hodgkin Lymphoma	Japan	Clinigen KK	16 Dec 2002
Hairy Cell Leukemia	United States	Janssen Pharmaceuticals, Inc.	26 Feb 1993

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Myasthenia Gravis	Phase 3	United States	Merck Healthcare KGaA	25 Jun 2024
Myasthenia Gravis	Phase 3	Japan	Merck Healthcare KGaA	25 Jun 2024
Myasthenia Gravis	Phase 3	Argentina	Merck Healthcare KGaA	25 Jun 2024
Myasthenia Gravis	Phase 3	Australia	Merck Healthcare KGaA	25 Jun 2024
Myasthenia Gravis	Phase 3	Georgia	Merck Healthcare KGaA	25 Jun 2024
Myasthenia Gravis	Phase 3	Poland	Merck Healthcare KGaA	25 Jun 2024
Myasthenia Gravis	Phase 3	Taiwan Province	Merck Healthcare KGaA	25 Jun 2024
Myasthenia Gravis	Phase 3	United Kingdom	Merck Healthcare KGaA	25 Jun 2024
Multiple Sclerosis, Chronic Progressive	Phase 3	United Kingdom	Merck Serono Ltd.	25 Jun 2021
Lupus Nephritis	Preclinical	Canada	BioNxt Solutions, Inc.	01 Dec 2024

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02115295 (CLIA, Pubmed \| Cancer)	Phase 2	Relapsing acute myeloid leukemia FLT3‐mutated AML	66	Cladribine 5 mg/m2	eurayivjkn(gnpeohkixg) = pkkzqlyebd qeglqqujml (lyuxhulfdv ) View more	Positive	15 Apr 2025
NCT02115295 (CLIA, Pubmed \| Cancer)	Phase 2	Relapsing acute myeloid leukemia FLT3‐mutated AML	66	Sorafenib 400 mg	tcdcybbozq(yqzmrngnmz) = hdkbonsshu ipjbegxany (bdkfllysce ) View more	Positive	15 Apr 2025
P12-1.009 (AAN2025)	Not Applicable	Multiple Sclerosis	83	Cladribine years 1+2	hymsjvkmub(iidouxflff) = oxtgshxyhz iokzvhiciv (kexcnocguk ) View more	Positive	07 Apr 2025
P8-1.009 (AAN2025)	Not Applicable	Multiple Sclerosis	835	Retreating cladribine course	qzwtbszqip(zjcsxayqqr) = bzsyusnzga xtuwktwzxe (jnmjbxvfpw ) View more	Positive	07 Apr 2025
P8-1.009 (AAN2025)	Not Applicable	Multiple Sclerosis	835	Switching to another therapy	qzwtbszqip(zjcsxayqqr) = zatyqsfoef xtuwktwzxe (jnmjbxvfpw ) View more	Positive	07 Apr 2025
P10-1.007 (AAN2025)	Not Applicable	Multiple Sclerosis	112	Cladribine (Pregnancy exposure after LMP)	mkdcmmqtty(jvhntxrbhv) = evxhqshluh anrhxrcyfm (aefjcyrttn ) View more	Positive	07 Apr 2025
P10-1.007 (AAN2025)	Not Applicable	Multiple Sclerosis	112	Cladribine (Pregnancy exposure during last 6-months before LMP)	qvxulofdfg(nzrjsthput) = iqgspuotix uiymoythbp (bujhlkuddk ) View more	Positive	07 Apr 2025
NCT03364036 (MAGNIFY-MS, Pubmed \| Front Immunol)	Phase 4	Multiple sclerosis relapse lymphocyte dynamics \| serum proteins \| sNfL	270	Cladribine tablets (CladT)	hxaqaakwuu(xtdcvtbcmb) = consistent with previous reports vrimqdippo (njombyjdhd )	Positive	03 Feb 2025
NCT04783935 (MAGNIFY-MS, CTgov)	Phase 4	Multiple Sclerosis	219	Cladribine	rhllrqgnuw = dfxuswgtms kssvtufeho (iwkptrhrrt, kzlyeccdya - hxzcxfkjrp) View more	-	22 Jan 2025
ASH2024 Manual	Phase 2	Hairy Cell Leukemia Second line	62	Cladribine with Concurrent Rituximab	smxiffbfzs(qwcjzqivrz) = nnwjdmxltd rospeludij (zszubfrwcn ) View more	Positive	09 Dec 2024
ASH2024 Manual	Phase 2	Hairy Cell Leukemia Second line	62	Cladribine Alone	smxiffbfzs(qwcjzqivrz) = udumxtqhzd rospeludij (zszubfrwcn ) View more	Positive	09 Dec 2024
NCT04797767 (4288Phase I Trial, ASH2024)	Phase 1	Acute Myeloid Leukemia \| Myeloid Tumor	20	Venetoclax 200 mg	nganhdqkss(ainbyzwyom) = nfgwfdsiyl tramouppzc (elbjlgximz, 5.1 months - not reached) View more	Positive	09 Dec 2024
ASH2024	Not Applicable	-	-	Cladribine, Idarubicin, and Cytarabine (CLIA) + Gilteritinib	yfyrdhktsw(eteomesqlp) = n = 5 qnyezehtuh (giztbmqzps ) View more	-	08 Dec 2024
NCT04708054 (ASH2024)	Phase 2	Acute Myeloid Leukemia \| Myelodysplastic Syndromes	-	Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen	yfjlrfptfu(vbdjzgflpq) = kchltlhvkt sdfmutxdqe (eqxnczfryi, 23 - 50) View more	-	08 Dec 2024